Clinical trials: Myeloma, Plasma-Cell
Relapsed/Refractory Multiple Myeloma
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT06508983
- Testing
- SG301 Injection, pomalidomide, dexamethasone
- Where
- 12 sites in China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Multiple Myeloma
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for…
- Trial name
- NCT06179888
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 74 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a…
- Trial name
- PD + RD (NCT02030483)
- Testing
- Palbociclib, Dexamethasone, Lenalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Weill Medical College of Cornell University
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma, Disease of the Marrow
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Developing an MRI protocol at 1.5 T allowing quantification of the hematopoietic, fatty and trabecular moieties of marrow. An ideal protocol would differentiate red marrow from neoplastic cellular infiltration, and detect loss of…
- Conditions
- Multiple Myeloma, Disease of the Marrow, Osteoporosis
- Trial name
- NCT01880762
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Multiple Myeloma
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
This is a single-arm and open-label study to explore XVRd (ATG-010, Bortezomib, Lenalidomide and Dexamethasone) regimen in high-risk newly diagnosed multiple myeloma.The primary objective of the dose escalation study is to…
- Trial name
- NCT05422027
- Testing
- Selinexor, Bortezomib, Lenalidomide
- Where
- 4 sites in China
- Volunteers
- 42 people
- Sponsor
- Xia Zhongjun
Multiple Myeloma
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher…
- Trial name
- NCT00116961
- Testing
- Velcade, Doxil, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
This is randomized, multicentre study aimed to compare a standard maintenance therapy with Interferon-Dexamethasone with an experimental therapy based on Thalidomide-Dexamethasone in patients with multiple myeloma who responded…
- Trial name
- NCT00633542
- Testing
- thalidomide, interferon alpha
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Università Politecnica delle Marche
Dose Escalation and Safety
NXC-201 (formerly HBI0101) Multiple Myeloma
It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients
- Trial name
- NCT04720313
- Testing
- NXC-201 (formerly HBI0101)
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hadassah Medical Organization
Multiple Myeloma
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
- Trial name
- NCT05776979
- Testing
- Isatuximab, lenalidomide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY).
- Trial name
- NCT01241396
- Testing
- Any MMY treatment
- Where
- 159 sites in Algeria, Austria and 19 more
- Volunteers
- 2,396 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM.
- Trial name
- LENDER (NCT03809780)
- Testing
- Lenalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Kosin University Gospel Hospital
Multiple Myeloma
Cardiovascular Complications of Carfilzomib Treatment
Accumulating evidence supports the hypothesis of a pathophysiological role of the Ubiquitin Proteasome System (UPS) in the process of atherosclerosis and vascular function.
- Trial name
- NCT03543579
- Where
- Greece
- Volunteers
- 46 people
- Sponsor
- University of Athens
Multiple Myeloma
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
- Trial name
- NCT01430546
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- Hareth Nahi
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or…
- Conditions
- DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00066638
- Testing
- Romidepsin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral Neuropathy, Toxicity Due to Chemotherapy
Acupuncture for Chemotherapy-induced Peripheral Neuropathy
The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.
- Conditions
- Peripheral Neuropathy, Toxicity Due to Chemotherapy, Lymphoma, Multiple Myeloma
- Trial name
- NCT01892852
- Testing
- Acupuncture
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Pusan National University Hospital
Multiple Myeloma
Thalidomide to Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition…
- Trial name
- NCT00218855
- Testing
- thalidomide
- Where
- Norway
- Volunteers
- 363 people
- Sponsor
- Norwegian University of Science and Technology
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00398515
- Testing
- lenalidomide, temsirolimus, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.